Juniper continues its investment in oral solid dose services

Published: 28-Jun-2018

The CDMO specialising in the development of challenging small molecules has made a $1.7 million investment

Juniper Pharma Services (JPS), a CDMO specialising in the development of challenging small molecules, is continuing its strategic investment in oral solid dose manufacturing with a $1.7 million purchase of three additional pieces of processing equipment.

This investment enhances JPS’ commitment to rapidly transform promising molecules into successful products for unmet medical needs and will ultimately lead to vital medicines reaching patients quicker.

The company has invested in three new pieces of top-specification solid dosage processing equipment: Gerteis MINI-PACTOR roller compactor, KG Pharma RoTab Bilayer tablet press and an O’Hara Labcoat Film Coater.

Following the successful implementation and high client demand of the original set of this equipment 12 months ago, JPS has invested in a duplicate process chain that will be fully operational by the end of June.

Located in Juniper Pharma Services’ Nottingham-based clinical manufacturing site, this new equipment will support client demands and deadlines by improving efficiency of drug production timelines.

JPS’ sustained investment in solid oral dosage processing equipment aligns to the increasing demand in the development of orphan and precision medicines and low volume commercial manufacturing.

Claire Madden-Smith, Senior VP at Juniper Pharma Services, said: “This significant investment signals our commitment to expanding our services to meet with the growing demand in solid oral dosage form development; a demand that is particularly prominent for difficult to formulate compounds in which JPS specialises."

"Our new equipment will greatly contribute to the niche manufacturing requirements of our clients, and enable JPS to work towards solving even more drug development challenges for unmet medical needs.”

You may also like